- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Fazirsiran Injection, Placebo
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 298
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Abdominal Pain, GI Disorders, Digestion
- Interventions
- Radicle GI Health Placebo Control Form 1, Radicle GI Health Active Study Product 1.1 Usage, Radicle GI Health Placebo Control Form 2, Radicle GI Health Active Study Product 2.1 Usage, Radicle GI Health Placebo Control Form 3, Radicle GI Health Active Study Product 3.1 Usage, Radicle GI Health Placebo Control Form 4, Radicle GI Health Active Study Product 4.1 Usage, Radicle GI Health Placebo Control Form 5, Radicle GI Health Active Study Product 5.1 Usage, Radicle GI Health Placebo Control Form 7, Radicle GI Health Active Study Product 7.1 Usage, Radicle GI Health Placebo Control 7.2, Radicle GI Health Active Study Product 7.2.1 Usage, Radicle GI Health Placebo Control 7.3.0, Radicle GI Health Active Study Product 7.3.1 Usage, Radicle GI Health Placebo Control 7.4.0, Radicle GI Health Active Study Product 7.4.1 Usage
- Dietary Supplement
- Lead sponsor
- Radicle Science
- Industry
- Eligibility
- 21 Years to 105 Years
- Enrollment
- 4,607 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Del Mar, California
- Conditions
- Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Obesity
- Interventions
- Not listed
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
- Interventions
- Treatment-inhaled tPA
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 5 Years to 24 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Chicago, Illinois • Ann Arbor, Michigan + 3 more
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, Renal Cancer
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2026
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Dopamine, Protein-Losing Enteropathies, Lymphatic System, Lymph, Catecholamine, Single-ventricle, Congenital Heart Disease
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Colorectal Cancer
- Interventions
- monoclonal antibody F19, iodine I 131 monoclonal antibody F19
- Biological · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • New York, New York
- Conditions
- Breast Cancer, Gastric Cancer, Ovarian Cancer
- Interventions
- HER-2/neu intracellular domain protein, therapeutic autologous dendritic cells
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
- Interventions
- BI 765049, ezabenlimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more
- Conditions
- Pancreatic Cancer
- Interventions
- ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT
- Biological · Drug · Procedure
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 2,565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 39
- States / cities
- Tucson, Arizona • Davis, California • Orange, California + 31 more
- Conditions
- Hepatic Insufficiency, Hypoalbuminemia
- Interventions
- Orally administered labeled glycerol
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Hepatocellular Carcinoma
- Interventions
- [18F]FAPI-74 PET/CT
- Drug
- Lead sponsor
- SOFIE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more
- Conditions
- Crohns Disease
- Interventions
- Examinations
- Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 5 Years to 15 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hemophilia, AIDS
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years to 100 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 15
- States / cities
- La Jolla, California • Los Angeles, California • Indianapolis, Indiana + 11 more
- Conditions
- Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma, Kidney Carcinoma, Liver Carcinoma, Malignant Solid Neoplasm, Multiple Myeloma, Prostate Carcinoma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ondansetron, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
- Conditions
- Microsatellite Stable, Mismatch Repair Protein Proficient, Stage III Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Bevacizumab, Capecitabine, Specimen collection, Pembrolizumab
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
- Interventions
- Lanifibranor, Placebo, Empagliflozin
- Drug
- Lead sponsor
- Inventiva Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 26
- States / cities
- Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more
- Conditions
- Multiple Myeloma, Diarrhea
- Interventions
- Colesevelam Pill
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells, Blasts Under 20 Percent of Bone Marrow Nucleated Cells, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Eosinophilia, Hepatomegaly, Hypereosinophilic Syndrome, JAK2 Gene Mutation, Splenomegaly, TEL-JAK2 Fusion Protein Expression
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Portland, Oregon • Salt Lake City, Utah + 1 more
- Conditions
- Crohn's Disease, Intestinal Fibrosis, Inflamatory Bowel Disease, Intestinal Strictures Related to Crohn´s Disease
- Interventions
- Ga68-FAPI-46
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Metastatic Prostate Carcinoma, Multiple Myeloma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Chart Review, Paracentesis, Positron Emission Tomography
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 147
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more
- Conditions
- Breast Neoplasm, Colorectal Neoplasm, Female Reproductive System Neoplasm, Health Care Provider, Lymphoma, Plasma Cell Myeloma
- Interventions
- Best Practice, Educational Intervention, Internet-Based Intervention, Questionnaire Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas